Practioner's Doctor No. U 015612-8

IN THE UNITED STATES I

TFW (755

PATENT

	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Pat of	tent application
	Inventor(s)
for	
	Title of invention
	OR
Ap	re application of: WILLIAM MARRITT plication No.: 10/523,455 Group No.: 1755 ed: JANUARY 28, 2005 Examiner: N/A r: POLYURONIC ACID DERIVATIVE AND AQUEOUS INK COMPOSITION COMPRISING POLYURONIC ACID DERIVATIVE
P.	ommissioner for Patents O. Box 1450 exandria, VA 22313-1450
	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))
	CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)
I he	ereby certify that, on the date shown below, this correspondence is being:
	MAILING
×	deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.
	37 C.F.R. 1.8(a) 37 C.F.R. 1.10*
×	with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No (mandatory)
	TRANSMISSION transmitted by facsimile to the Patent and Trademark Office.
Da	te: March 23, 2006 CLIFFORD J. MASS JULIAN GHEN
*	(type or print name of person certifying) Only the date of filing (\S 1.6) will be the date used in a patent term adjustment calculation, although the date on any

NOTE: 37 C.F.R. 1.98(b):

(5)

Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.

(2) Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication

date.

(3) Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.

(4) Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.

Each publication listed in an information disclosure statement must be identified by publisher, author (fi any), title, relevant pages of the publication,,date, and place of

publication.

WARNING: No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).

NOTE: The "filing date of a national application" under 37 C.F.R. 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sent by the International Bureau, and an English translation if filed in another language; (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. 37 C.F.R. 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

NOTE: "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuationsin-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39). NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

If a fee is required, please charge deposit account 12-0425.

SIGNATURE OF PRACTITIONER

- May 20302 for

Reg. No. 30,086

Tel. No.: (212)708-1890

Customer No.: 00140

CLIFFORD J. MASS

(type or print name of practitioner)

LADAS & PARRY

P.O. Address

26 WEST 61ST STREET

NEW YORK, NEW YORK 10023

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: WILLIAM MARRITT

Application No.: 10/523,455 Filed: JANUARY 28, 2005 Group No.: 1755 Examiner: N/A

POLYURONIC ACID DERIVATIVE AND AQUEOUS INK COMPOSITION COMPRISING

POLYURONIC ACID DERIVATIVE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached references which are also listed on the attached Form PTO-1449.

Respectfully submitted,
CLIFFORD J. MASS
LADAS & PARRY LLP
26 WEST 61 ST STREET
NEW YORK, NEW YORK 10023
REG.NO.30.086(212)708-1890

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING \boxtimes deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. 1.8(a) 37 C.F.R. 1.10* \boxtimes as "Express Mail Post Office to Address" with sufficient postage as first class mail. Mailing Label No._ (mandatory) TRANSMISSION transmitted by facsimile to the Patent and Trademark Office. Date: March 23, 2006 Signature CLIFFORD J. MASS

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

> "Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

FORM PTO-1449

EXAMINER:

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.							
U 015612-8	10/523,455							
APPLICANT								
William MARRITT								
FILING DATE	GROUP							
JANUARY 28, 2005	1755							

7. 2000	W (Ose several sil		FILING DATE			GROUP			
MAR 3 7. 2000 (Use several sheets if necessary)				JANUARY 28, 2005			1755		
Temper		U.S. F	PATENT DO	CUMENT	rs				
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE		NAME		FILING DATE IF APPROPRIATE		
. ,	AA	6,242,529	06/2001		Marritt et al.				
	AB	6,132,502	10/2000		Yatake				
	AC	6,051,057	04/2000		Yatake et al.				
	AD								
	AE								
	AF								
	AG								
	АН								
	AI					,			
	AJ								
	AK			· ·					
		FOREIG	N PATENT I	OOCUME	ENTS		 		
		D0CUMENT NUMBER	DAT	r E	COUNTRY	√	TRANSLATION		
	<u> </u>		·		COONTRI		YES	NO	
	AL	0 894 835	02/19	99	EP			 	
	AM	01/94476	12/20		wo			—	
	AN	2000-169769	06/20)00	JP		х	 	
	AO								
	AP				<u> </u>				
	ОТ	HER ART (Includ	ling Author, 7	ritle, Date	e, Pertinent Dates, Etc	.)			
	AR	Computer-Generated and Patent Abstracts	English Tran of Japan of J	ıslation of P 2000-1 <i>6</i>	f Specification and Cla	aims 2000			
	AS								
	AT								
EXAMINER				DATE	CONSIDERED				

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.